Rinvoq 45 mg

RINVOQ 45 MG is an extended-release tablet containing upadacitinib, used for managing inflammatory conditions. This medication is designed for oral administration and is manufactured by AbbVie Corporation in Canada.

RINVOQ 45 MG is primarily used for the treatment of inflammatory conditions. It is often prescribed for managing symptoms associated with rheumatoid arthritis, psoriatic arthritis, and other autoimmune disorders. The active ingredient, upadacitinib, works by modulating the immune response to reduce inflammation and alleviate pain.

Common effects of RINVOQ 45 MG may include mild to moderate gastrointestinal discomfort, such as nausea or diarrhea. Some users may experience fatigue or headaches. These effects are generally temporary and may subside as the body adjusts to the medication.

RINVOQ 45 MG should be handled with care and stored as directed. It is important to follow the prescribed dosage and administration instructions provided by a healthcare professional. Patients with a history of severe infections or liver issues should consult their doctor before starting this medication.

RINVOQ 45 MG may interact with certain medications, including those that affect the immune system or are metabolized by the liver. It is advisable to inform your healthcare provider about all medications you are taking to avoid potential interactions. Alcohol consumption should be moderated while using this medication.